Int J Gynecol Obstet 2020; 148: 79–86 wileyonlinelibrary.com/journal/ijgo | 79 © 2019 Internatonal Federaton of Gynecology and Obstetrics Received: 23 April 2019 | Revised: 19 July 2019 | Accepted: 24 September 2019 | First published online: 10 October 2019 DOI: 10.1002/ijgo.12981 CLINICAL ARTICLE Gynecology An Israeli Gynecologic Oncology Group study of statn use and endometrial cancer prognosis Yakir Segev 1, * | Ofer Gemer 2 | Limor Helpman 3,4 | Nasreen Hag-Yahia 3,4 | Ram Eitan 5 | Oded Raban 5 | Zvi Vaknin 6 | Alon Ben-Arie 7 | Amnon Amit 8 | Tally Levy 9 | Ahmed Namazov 2 | Michael Voldarsky 2 | Inbar Ben Shachar 10 | Ilan Atlas 11 | Ilan Bruchim 12 | Ofer Lavie 6 1 Department of Obstetrics and Gynecology, Carmel Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel 2 Department of Obstetrics and Gynecology, Barzilai Medical Center, Faculty of Health Sciences, Ben-Gurion University, Ashkelon, Israel 3 Department of Obstetrics and Gynecology, Meir Medical Center, Kfar Saba, Israel 4 Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel 5 Department of Obstetrics and Gynecology, Rabin Medical Center, Sackler School of Medicine, Tel-Aviv University, Peta Tikva, Israel 6 Department of Obstetrics and Gynecology, The Yitzhak Shamir Medical Center, Tzrifn, Israel 7 Department of Obstetrics and Gynecology, Kaplan Medical Center, Hebrew University, Rehovot, Israel 8 Department of Obstetrics and Gynecology, Rambam Medical Center, Rappaport Faculty of Medicine, Technion, Haifa, Israel 9 Department of Obstetrics and Gynecology, Wolfson Medical Center, Sackler School of Medicine, Tel-Aviv University, Holon, Israel 10 Department of Obstetrics and Gynecology, Ziv Medical Center, Bar Ilan University, Zefat, Israel 11 Department of Obstetrics and Gynecology, Poriya Medical Center, Bar Ilan University, Tiberia, Israel 12 Department of Obstetrics and Gynecology, Hillel Yafe Medical Center, Rappaport Faculty of Medicine, Technion, Hedera, Israel Abstract Objectve: To assess whether statn use by endometrial cancer patents was associated with a survival advantage. Methods: A retrospectve chart review study, by the Israeli Gynecologic Oncology Group, of consecutve endometrial cancer patents who underwent surgery in one of 11 medical centers between 2002 and 2014. Clinical and pathological reports, and measures of survival were compared between statn users and nonusers. Kaplan-Meier and Cox proportonal hazard models were used to assess the efect of using statns on survival measures. Results: Over a mean follow-up period of 6.2 years (range, 1–12 years) for 2017 endo- metrial cancer patents with complete data, 663 (32.8%) used statns prior to diagnosis and 1354 (67.1%) did not. No statstcally signifcant diferences between the groups were observed for most demographic and clinical characteristcs. There was no difer- ence between statn users and nonusers in 5-year recurrence-free survival (82% vs 83%; P=0.508), disease-specifc survival (86% vs 84%; P=0.549), or overall survival (77% vs 75%; P=0.901). Conclusions: In this large cohort of patents with endometrial cancer, no signifcant associatons were found between use of statns and endometrial cancer survival. KEYWORDS Endometrial cancer; Israeli Gynecologic Study Group; Statns; Survival